Immunovaccine has received clearance from Health Canada to conduct a clinical trial on a vaccine for RSV.

The company’s approach to infectious disease is a new approach that uses the company‚Äôs proprietary DepoVax technology and has been effective in protecting animals against RSV in pre-clinical trials.

Immunovaccine has conducted Phase I human studies with its vaccines for cancer treatment. But this will be the first clinical trial of a DepoVax-based vaccine for protection against infectious disease.